Presentation by Jan Törnell of Oncorena and orellanine as treatment for renal cancer – Aqilion

The Oncorena company presented at the Park Annual meeting September 2014 by the CEO Jan Tornell. This future treatment is intended for patients with advanced kidney cancer.

No

Yes

Aqilion uses cookies in order to optimize your experience and use of our website as well as to be able to analyze the users’ usage of the website. Choose yourself if you would like to accept the cookies. Before you make your choice we encourage you to read our cookie policy. Do you accept our cookie policy?